The Centers for Medicare & Medicaid Services announced the first 10 drugs to be negotiated by Medicare. As CMS and pharmaceutical manufacturers prepare for negotiations, they will consider not only the effectiveness of these drugs, but also their financial performance and investment over the years.
To create a public benchmark of these measures, ATI collected data from FDA labels, Evaluate Pharma and Omnium databases, the CMS spending dashboard, and proprietary data.
For each drug, we present a summary of its time on the market, use in Medicare, clinical development activity and investment, global and U.S. sales, its position in the manufacturer’s portfolio, and deal history.
Read More
Read More